…
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
ADC Therapeutics SA is a Swiss oncology company that develops antibody-drug conjugates (ADCs) and commercializes the FDA-approved ZYNLONTA for certain relapsed or refractory large B-cell lymphomas. Long-term growth may be supported by pipeline readouts, label and geographic expansion of ZYNLONTA, and partnerships; investors may find the company attractive because an approved therapy validates its ADC platform and provides initial revenue.
Key risks are clinical or regulatory setbacks, weak commercial uptake of the sole approved product, intense oncology competition, manufacturing complexity and the likely need for additional financing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-09-30 |
| Income before tax | -142.78M | -157.68M | -195.42M | -154.66M | -154.66M |
| Net income | -142.62M | -157.85M | -240.05M | -155.80M | -155.80M |
| Selling general administrative | 36.56M | 64.47M | 48.42M | 141.06M | 141.06M |
| Selling and marketing expenses | 43.37M | 21.44M | 57.46M | 69.05M | 69.05M |
| Gross profit | 73.68M | 64.89M | 67.03M | 205.33M | 205.33M |
| Reconciled depreciation | 1.88M | 3.28M | 2.83M | 2.33M | 2.33M |
| Ebit | -108.38M | -105.92M | -150.03M | -110.44M | -123.63M |
| Ebitda | -106.50M | -102.65M | -146.76M | -108.06M | -98.83M |
| Depreciation and amortization | 1.88M | 3.28M | 3.27M | 2.39M | 24.79M |
| Operating income | -108.38M | -130.65M | -165.99M | -123.63M | -123.63M |
| Other operating expenses | 189.74M | 201.49M | 235.54M | 333.54M | 333.54M |
| Interest expense | 51.63M | 50.21M | 46.33M | 36.92M | 36.92M |
| Tax provision | 1.01M | 0.17M | -2.99M | 1.14M | 1.14M |
| Interest income | 8.81M | 12.27M | 6.62M | 17.97M | 17.97M |
| Net interest income | -42.82M | -37.94M | -39.58M | -18.95M | -18.95M |
| Income tax expense | -0.16M | 0.17M | 39.11M | 1.14M | 1.14M |
| Total revenue | 81.36M | 70.84M | 69.56M | 209.91M | 209.91M |
| Total operating expenses | 182.06M | 195.54M | 233.01M | 328.96M | 328.96M |
| Cost of revenue | 7.67M | 5.95M | 2.53M | 4.58M | 4.58M |
| Total other income expense net | -34.40M | -27.03M | -29.43M | -33.56M | -31.03M |
| Net income from continuing ops | -142.62M | -157.85M | -178.51M | -155.80M | -155.80M |
| Net income applicable to common shares | - | - | - | -155.80M | -155.80M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-09-30 |
| Total assets | 323.15M | 321.98M | 354.78M | 529.17M | 529.17M |
| Intangible assets | - | - | - | 14.36M | 14.36M |
| Other current assets | 11.70M | 17.82M | 16.33M | 23.50M | 28.04M |
| Total liab | 508.98M | 524.62M | 503.03M | 440.44M | 440.44M |
| Total stockholder equity | -185.83M | -202.64M | -148.25M | 88.73M | 88.73M |
| Deferred long term liab | - | - | - | 0.95M | 0.95M |
| Other current liab | 57.99M | 61.07M | 49.17M | 68.49M | 73.03M |
| Common stock | 11.08M | 8.43M | 7.31M | 7.31M | 7.31M |
| Capital stock | 11.08M | 8.43M | 7.31M | 7.31M | 7.31M |
| Retained earnings | -1635.94M | -1493.32M | -1335.47M | -1080.68M | -1080.68M |
| Other liab | - | - | - | 25.33M | 25.33M |
| Other assets | - | - | 0.00M | 28.61M | 28.61M |
| Cash | 261.34M | 250.87M | 278.60M | 326.44M | 326.44M |
| Total current liabilities | 70.16M | 80.47M | 67.67M | 98.96M | 98.96M |
| Net debt | 177.67M | -127.87M | -154.22M | -209.07M | -209.07M |
| Short term debt | 3.00M | 1.37M | 2.93M | 1.10M | 13.57M |
| Short long term debt | 3.00M | - | - | 12.47M | 12.47M |
| Short long term debt total | 439.01M | 123.00M | 124.38M | 117.38M | 117.38M |
| Other stockholder equity | 1439.54M | 1283.67M | 1180.00M | 1165.73M | 1006.77M |
| Property plant equipment | - | - | - | 9.98M | 9.98M |
| Total current assets | 306.33M | 307.39M | 336.29M | 446.01M | 446.01M |
| Long term investments | - | 0.00M | 1.65M | 31.15M | 31.15M |
| Net tangible assets | - | - | - | 75.32M | 75.32M |
| Net receivables | 29.12M | 20.32M | 25.18M | 72.97M | 77.71M |
| Long term debt | 112.45M | 113.63M | 112.73M | 97.24M | 97.24M |
| Inventory | 4.18M | 18.39M | 16.18M | 18.56M | 18.56M |
| Accounts payable | 9.18M | 18.03M | 15.57M | 12.35M | 12.35M |
| Accumulated other comprehensive income | -0.52M | -1.42M | -0.09M | 155.33M | 155.33M |
| Non currrent assets other | 15.52M | 1.16M | 0.71M | 0.90M | 0.90M |
| Non current assets total | 16.82M | 14.59M | 18.49M | 83.15M | 83.15M |
| Capital lease obligations | 1.57M | 9.37M | 11.65M | 7.66M | 7.66M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-09-30 |
| Investments | - | -0.87M | -2.40M | -2.51M | -2.51M |
| Change to liabilities | - | - | - | 0.31M | 0.31M |
| Total cashflows from investing activities | 0.40M | -0.87M | - | -2.51M | -2.51M |
| Net borrowings | - | - | - | -6.50M | -6.50M |
| Total cash from financing activities | 150.94M | 97.05M | 73.88M | -0.59M | -0.59M |
| Change to operating activities | - | - | - | 16.55M | 16.55M |
| Net income | -142.62M | -157.85M | -240.05M | -155.80M | -155.80M |
| Change in cash | 10.47M | -27.73M | -47.84M | -140.10M | -140.10M |
| Begin period cash flow | 250.87M | 278.60M | 326.44M | 466.54M | 466.54M |
| End period cash flow | 261.34M | 250.87M | 278.60M | 326.44M | 326.44M |
| Total cash from operating activities | -141.17M | -123.83M | -118.69M | -136.79M | -136.79M |
| Issuance of capital stock | 86.28M | 60.51M | -0.06M | 6.13M | 6.13M |
| Depreciation | 1.88M | 3.28M | 3.27M | 2.33M | 2.33M |
| Other cashflows from investing activities | - | - | - | -0.21M | -0.21M |
| Change to inventory | -2.38M | -3.73M | 1.61M | -8.96M | -8.96M |
| Change to account receivables | -8.79M | 4.77M | 47.79M | -42.75M | -42.75M |
| Sale purchase of stock | - | - | - | -0.22M | -0.22M |
| Other cashflows from financing activities | -1.51M | 36.55M | 73.88M | -4.32M | -5.49M |
| Change to netincome | - | - | - | 49.69M | 49.69M |
| Capital expenditures | 0.26M | 0.87M | 3.22M | 2.30M | 2.30M |
| Change in working capital | -25.36M | 3.83M | 44.27M | -33.01M | -33.01M |
| Stock based compensation | 6.91M | 6.57M | 13.49M | 49.32M | 49.32M |
| Other non cash items | 18.02M | 20.34M | 23.23M | 1.07M | 1.07M |
| Free cash flow | -141.44M | -124.70M | -121.90M | -139.09M | -139.09M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ADCT ADC Therapeutics SA |
-0.07 4.96% |
1.34 | - | - | 1.75 | 3.42 | 0.50 | -1.43 |
| MKKGY Merck KGaA ADR |
0.45 1.38% |
33.07 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
2.27 1.38% |
167.12 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.31 1.47% |
21.43 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
43.15 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
| Name | Title | Year Born |
|---|---|---|
| Dr. Ameet Mallik M.B.A., M.S. | CEO & Director | 1972 |
| Dr. Christopher J. Martin DPHIL, Ph.D. | Co-Founder & Non-Exec. Director | 1959 |
| Ms. Jennifer Creel | Chief Financial Officer | 1971 |
| Dr. Michael Mulkerrin Ph.D. | Chief Technical Operations Officer | NA |
| Dr. Patrick van Berkel Ph.D. | Chief Scientific Officer | 1968 |
| Amanda Hamilton | Investor Relations Officer | NA |
| Ms. Susan Romanus | Chief Compliance & Quality Officer | 1965 |
| Mr. Peter J. Graham Esq. | Chief Legal Officer | 1967 |
| Ms. Kimberly Pope | Sr. VP & Chief People Officer | 1966 |
| Dr. Joseph Camardo Ph.D. | Chief Medical Officer | 1953 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.